Cannabinoid Receptor
Cannabinoid Receptor
Cannabinoid receptors are currently classified into three groups: central (CB1), peripheral (CB2) and GPR55, all of which are G-protein-coupled. CB1 receptors are primarily located at central and peripheral nerve terminals. CB2 receptors are predominantly expressed in non-neuronal tissues, particularly immune cells, where they modulate cytokine release and cell migration. Recent reports have suggested that CB2 receptors may also be expressed in the CNS. GPR55 receptors are non-CB1/CB2 receptors that exhibit affinity for endogenous, plant and synthetic cannabinoids. Endogenous ligands for cannabinoid receptors have been discovered, including anandamide and 2-arachidonylglycerol.
Cannabinoid Receptor Isoform Specific Products
All Product Categories
-
Cannabinoid Receptor Inhibitors
(37)
View all products
-
Cannabinoid Receptor Agonists
(141)
View all products
-
Cannabinoid Receptor Antagonists
(76)
View all products
-
Cannabinoid Receptor Activators
(15)
View all products
-
Cannabinoid Receptor Modulators
(24)
View all products
-
Cannabinoid Receptor Chemical
(1)
View all products
-
Cannabinoid Receptor Inducer
(1)
View all products
-
Cannabinoid Receptor Degrader
(1)
View all products
-
Cannabinoid Receptor Controls
(2)
View all products
-
Cannabinoid Receptor Ligands
(13)
View all products
-
Cannabinoid Receptor Related Products (449)
Related Products (449)
-
Antibodies (1)
-
Cannabinoid Receptor Isoform Comparison
-
AM841
0 ImagesCat. No.: HY-149933CAS No.: 871978-21-1AM841 is a high-affinity electrophilic ligand. AM841 interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. AM841 reduces Forskolin (HY-15371)-stimulated cAMP accumulation. AM841 also slows gastrointestinal motility.
-
TM38837
0 ImagesCat. No.: HY-157312CAS No.: 1034264-77-1TM38837 is an orally active and selective inverse agonist of cannabinoid receptor 1 (CB1) with an IC50 of 24 nM. TM38837 has higher selectivity for CB1 than for CB2 (IC50: 4500 nM). TM38837 can reduce body weight, improve plasma inflammatory markers and glucose homeostasis.
-
Δ9-THCB
0 ImagesCat. No.: HY-N15177CAS No.: 60008-00-6Synonyms: Δ9-Tetrahydrocannabutol
-
Mead ethanolamide
0 ImagesCat. No.: HY-134615CAS No.: 169232-04-6Mead ethanolamide is an endogenous cannabinoid receptor agonist with Kd values of 753 nM and 1810 nM against CB1 and CB2, respectively.
-
O-2093
0 ImagesCat. No.: HY-103340CAS No.: 439080-01-0O-2093 is a selective endocannabinoid anandamide (AEA) reuptake inhibitor with IC50 of 17.3 μM.
-
N-(3-Hydroxyphenyl)-arachidonoyl amide
0 ImagesCat. No.: HY-W337358CAS No.: 183718-75-4N-(3-Hydroxyphenyl)-arachidonoyl amide (Compound 23) is an anandamide transport inhibitor with an IC50 of 21.3 μM.
-
Levonantradol hydrochloride
0 ImagesCat. No.: HY-122109ACAS No.: 70222-86-5Synonyms: l-Nantradol hydrochloride; CP 50556-1 hydrochlorideLevonantradol (l-Nantradol) hydrochloride is an analog of delta (9)-tetrahydrocannabinol. Levonantradol acting as a potent anti-analgesic agent.
-
PM226
0 ImagesCat. No.: HY-136238CAS No.: 1949726-13-9PM226 is a selective cannabinoid CB2R agonist (Ki (CB2R)=13 nM; EC50 (CB2R)=39 nM; Ki (CB1R) >40 μM;) with neuroprotective properties in vitro and vivo.
-
AM11542
0 ImagesCat. No.: HY-177425CAS No.: 152674-95-8AM11542 is a cannabinoid receptor 1 (CB1) agonist with a human CB1 Ki of 0.11 nM. AM11542 stabilizes the active conformational state of the CB1 receptor. AM11542 can be used for the research of obesity.
-
NIDA-41020
0 ImagesCat. No.: HY-103326CAS No.: 502486-89-7NIDA-41020 is a potent and selective cannabinoid receptor 1(CB1) antagonist with a Ki of 4.1 nM. NIDA-41020 was designed as a potential radioligand for use in positron emission tomography (PET).
-
γ-Linolenoyl monoethanolamide
0 ImagesCat. No.: HY-162298CAS No.: 150314-37-7γ-Linolenoyl monoethanolamide, a kind of fatty N-acyl ethanolamine, is an endocannabinoid.
-
RVD-Hpα
0 ImagesCat. No.: HY-P1397CAS No.: 1193362-76-3RVD-Hpα, an α-hemoglobin-derived peptide containing three additional amino acids, is a CB1 cannabinoid receptor agonist. RVD-Hpα is a positive allosteric modulator of cannabinoid receptor 2.
-
JHU-75528
0 ImagesCat. No.: HY-105238CAS No.: 947696-17-5JHU-75528 is a novel ligand of the cannabinoid receptor (CB1). JHU-75528 can be used in the research of imaging CB1 receptor.
-
CB2R antagonist 4
0 ImagesCat. No.: HY-175784CAS No.: 1341021-90-6CB2R antagonist 4 is a selective CB2R antagonist/inverse agonist with a pKi of 6.54. CB2R antagonist 4 shows a ≥11-fold selectivity towards CB2R over CB1R and can be utilized in neurological research.
-
UCM707
0 ImagesCat. No.: HY-103341CAS No.: 390824-20-1UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of Anandamide.
-
O-Arachidonoyl glycidol
0 ImagesCat. No.: HY-131995CAS No.: 439146-24-4O-Arachidonoyl glycidol (compound 1) is a 2-arachidonoylglycerol (2-AG) analog. O-Arachidonoyl glycidol inhibits cytosolic 2-oleoylglycerol (2-OG) hydrolysis with an IC50 value of 4.5 µM. O-Arachidonoyl glycidol blocks 2-OG hydrolysis in membrane fractions and anandamide hydrolysis with IC50s of 19, 12 µM, respectively.
-
BMS-812204
0 ImagesCat. No.: HY-12606CAS No.: 1494218-40-4BMS-812204 is a highly selective CB-1 receptor antagonist. BMS-812204 is promising for research of obesity and metabolic disorders.
-
CBR Agonist-1
0 ImagesCat. No.: HY-151105CBR Agonist-1 (27a-cis) is a cannabinoid receptor (CBR) agonist with the Ki values of 0.18 μM for CB1R and 1.22 μM for CB2R. CBR Agonist-1 (27a-cis) can be used in the study of endogenous cannabinoid system-related diseases.
-
GAT228
0 ImagesCat. No.: HY-120953CAS No.: 1446648-15-2GAT228, the enantiomer of GAT211, is an allosteric cannabinoid receptor 1 (CB1) ligand.
-
AB-FUBICA
0 ImagesCat. No.: HY-117403CAS No.: 1801338-22-6AB-FUBICA (Compound 13) is a CB1 and CB2 receptor agonist that activates G-protein coupled inwardly rectifying potassium channels (GIRK) by binding to CB1 and CB2 receptors, displaying notable cannabinoid-like activity. AB-FUBICA has EC50 values of 21 nM for CB1 and 15 nM for CB2. AB-FUBICA may be suitable for studying pain management, neurodegenerative diseases, and inflammation-related mechanisms.
